I start a new tranche on May 6th. It is a slow day here, I have about 40 minutes to kill. So I thought I'd write down a few of my thoughts.
First, here is the expiring tranche:
| Start | Current | Dividend | Pct Gain | R3K Gain | |
| AVG | $19.57 | $21.60 | $0.00 | 10.4% | 13.6% |
| CA | $29.54 | $31.86 | $1.00 | 11.2% | 13.6% |
| $22.79 | $28.94 | $0.57 | 29.5% | 13.6% | |
| NSR | $25.82 | $27.99 | $0.00 | 8.4% | 13.6% |
| $28.78 | $30.06 | $0.94 | 7.7% | 13.6% | |
| Totals | 13.4% | 13.6% |
It has really gained some serious ground these last few days.
Here is the current top fifty over 100 million list:
| Ticker | Mkt Cap | Date |
| ACHI | 543.42 | 24-Apr |
| ADMS | 310.65 | 24-Apr |
| APEI | 524.51 | 24-Apr |
| 569.57 | 24-Apr | |
| 1,884.99 | 24-Apr | |
| AGX | 476.53 | 24-Apr |
| 8,879.50 | 24-Apr | |
| 569.90 | 24-Apr | |
| 5,123.71 | 24-Apr | |
| 2,307.73 | 24-Apr | |
| CPLA | 816.00 | 24-Apr |
| 147,183.70 | 24-Apr | |
| 203.98 | 24-Apr | |
| DEPO | 1,639.16 | 24-Apr |
| ENTA | 690.80 | 24-Apr |
| EGL | 531.98 | 24-Apr |
| FLR | 8,934.39 | 24-Apr |
| GME | 4,384.47 | 24-Apr |
| GILD | 155,438.80 | 24-Apr |
| GORO | 183.13 | 24-Apr |
| HPQ | 60,599.72 | 24-Apr |
| ONE | 131.53 | 24-Apr |
| IQNT | 647.70 | 24-Apr |
| IDCC | 1,987.77 | 24-Apr |
| KING | 5,396.03 | 24-Apr |
| KFY | 1,635.69 | 24-Apr |
| LQDT | 282.48 | 24-Apr |
| MSB | 200.47 | 24-Apr |
| KORS | 12,761.32 | 24-Apr |
| NATH | 209.07 | 24-Apr |
| NHTC | 280.66 | 24-Apr |
| NSR | 1,537.92 | 24-Apr |
| NSU | 762.67 | 24-Apr |
| NLNK | 1,457.81 | 24-Apr |
| 1,131.44 | 24-Apr | |
| PFMT | 158.91 | 24-Apr |
| PETS | 351.56 | 24-Apr |
| PPC | 6,117.56 | 24-Apr |
| 4,604.91 | 24-Apr | |
| PSDV | 122.35 | 24-Apr |
| 111,435.90 | 24-Apr | |
| RPXC | 846.79 | 24-Apr |
| 142.96 | 24-Apr | |
| 582.22 | 24-Apr | |
| TSRA | 2,029.06 | 24-Apr |
| 1,084.45 | 24-Apr | |
| VEC | 271.04 | 24-Apr |
| VIAB | 28,812.40 | 24-Apr |
| 467.78 | 24-Apr | |
| WILN | 319.77 | 24-Apr |
Listing stocks I want to explore further:
- CSCO
- ENTA
- FLR
- GILD
- HPQ
- LQDT
- PMFT
- PSDV
- NLNK
Then throw in TNH, CTCM & CBI, which do not make this list but are high in my own version of the list. Finally, I will also include MNDO, which is a bit smaller in market cap. So a lucky 13? I clearly need one more - oh yeah, DEPO.
CSCO - hard to ignore Goldman Sachs placing on conviction list. They have a $34 target and toss in a 3% dividend. That is nothing to sneeze at. I do now think about whether the stock is also MFI Formula "worthy". In this case it is. Even selling in my May tranche, I do have CSCO in my August tranche (select) and December 31st (formula). That seems like enough conviction. Though I will buy on July 1st should Mr Random insist.
ENTA - I will admit that I do not fully understand this stock. they are at $37, down from $52 earlier this year. They are a biotech company, though they do have earnings to go along with their 52 employees. I will need to do some more research here to see what their pipeline looks like, but they will certainly make the first cut.
FLR - I took a pounding with my construction picks in August and November (AGX, FLR & CBI). They are down an average of 9.5%, though a couple months ago it was much much worse. So they have battled back. FLR feels like the least under-priced, so I will skip them.
GILD - again, pharmaceuticals have traditionally done very well in the MFI world. Who knows, GILD is US-based and the playbook has been to roll these up (see ACT or VRX) in Ireland or the UK to get some tax-savings. I do not know a lot about GILD, except that they have a drug that may be under some competitive fire. Historically, I have felt that markets over-react to this fear. I think GILD makes the cut to the next round.
More to follow.
FLR - I took a pounding with my construction picks in August and November (AGX, FLR & CBI). They are down an average of 9.5%, though a couple months ago it was much much worse. So they have battled back. FLR feels like the least under-priced, so I will skip them.
GILD - again, pharmaceuticals have traditionally done very well in the MFI world. Who knows, GILD is US-based and the playbook has been to roll these up (see ACT or VRX) in Ireland or the UK to get some tax-savings. I do not know a lot about GILD, except that they have a drug that may be under some competitive fire. Historically, I have felt that markets over-react to this fear. I think GILD makes the cut to the next round.
More to follow.
Posts
